India, Nov. 7 -- Cognition Therapeutics Inc. (CGTX), a clinical-stage biopharmaceutical company, released financial results for the third quarter, noting a lower loss due to increased income.
The company specializes in developing therapies for degenerative nerve disorders, especially in those where toxic oligomers drive disease progression. These include Lewy body dementia (DLB), Alzheimer's disease, geographic atrophy, and Parkinson's disease. Lead drug candidate Zervimesine is currently under a Phase 2 evaluation for treating DLB and Alzheimer's.
Q3 Financial Results:
Net loss for the three months ending September 30, 2026, was $4.14 million or $0.04 per share, while a loss of $4.93 million or $0.06 per share was recorded in the same p...